Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Cy5.5-Labeled and gadolinium-chelated chitosan nanoparticles

In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004.
[updated ].
Affiliations
Free Books & Documents
Review

Cy5.5-Labeled and gadolinium-chelated chitosan nanoparticles

Liang Shan.
Free Books & Documents

Excerpt

The Cy5.5-labeled and gadolinium (Gd(III))-chelated chitosan nanoparticles, abbreviated as Cy5.5-CNP-Gd(III), are an optical/magnetic resonance (MR) dual imaging agent synthesized by Nam et al. for multimodality imaging of tumors (1).

The idea of using multiple modalities in a single imaging session comes from the fact that modalities with high sensitivity have relatively poor resolution, while those with high resolution have relatively poor sensitivity (2, 3). Integration of multiple modalities in imaging would take the advantages of each modality and allow better characterization of diseases and disease processes (4, 5). To date, the most successful hybrid system is derived from the fusion of positron emission tomography (PET) and computed tomography (CT) (5-8). PET is highly sensitive and allows three-dimensional images that show the concentration and location of the radiolabeled tracers of interest, while CT provides high-resolution imaging of the anatomical structures. Because of limited soft-tissue contrast and high X-ray radiation that accompanies CT imaging, considerable effort has been invested in recent years toward development of PET/magnetic resonance imaging (MRI) hybrid systems in an attempt to generate combined functional and morphological images with excellent soft tissue contrast, good spatial resolution of the anatomy, and accurate temporal and spatial image fusion (9-11). In contrast, systems integrated with optical techniques have not been investigated as extensively. Considering the advantages of multichannel imaging with single or multiple probes and the low cost of studying reporter gene expression in animal models, optical imaging integrated with other modalities may provide information at the cellular and molecular levels, which is critical in preclinical studies (1, 2, 12).

Development of hybrid imaging technology has triggered great effort in probe development to boost the benefits of hybrid instrument technology (12-15). In the case of optical/MRI probe design, the challenge is turned around to incorporate enough paramagnetic ions for detection by the relatively low sensitivity of MRI. Nam et al. have developed a dual imaging probe (Cy5.5-CNP-Gd(III)) with water-soluble glycol chitosan and the probes were preferably accumulated within the tumor xenografts in vivo (1). Chitosan has been frequently used to make nanoparticles carrying imaging reporters as well as therapeutic agents (1, 12, 15). Generally, the positively charged chitosan polymer can coat around a nanoparticle core by electrostatic adsorption, and other components are embedded in the chitosan matrix during the coating process. All components can also be entrapped simultaneously in the chitosan matrix.

PubMed Disclaimer

Similar articles

References

    1. Nam T., Park S., Lee S.Y., Park K., Choi K., Song I.C., Han M.H., Leary J.J., Yuk S.A., Kwon I.C., Kim K., Jeong S.Y. Tumor targeting chitosan nanoparticles for dual-modality optical/MR cancer imaging. . Bioconjug Chem. 2010;21(4):578–82. - PubMed
    1. Cherry S.R. Multimodality in vivo imaging systems: twice the power or double the trouble? . Annu Rev Biomed Eng. 2006;8:35–62. - PubMed
    1. Delbeke D., Schoder H., Martin W.H., Wahl R.L. Hybrid imaging (SPECT/CT and PET/CT): improving therapeutic decisions. . Semin Nucl Med. 2009;39(5):308–40. - PubMed
    1. Cherry S.R. Multimodality imaging: beyond PET/CT and SPECT/CT. . Semin Nucl Med. 2009;39(5):348–53. - PMC - PubMed
    1. Patel C.N., Goldstone A.R., Chowdhury F.U., Scarsbrook A.F. FDG PET/CT in oncology: "raising the bar . Clin Radiol. 2010;65(7):522–35. - PubMed

LinkOut - more resources